tradingview
Key facts: Merck & Co., Inc. Q2 Sales $16.6B; sac-TMT Advances
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
benzinga
Why Merck Just Slashed Its Profit Outlook By Nearly 50%
Merck & Co. Inc. (NYSE:MRK) stock edged higher Tuesday after the drugmaker reported second-quarter results that topped Wall Street revenue expectations and posted a smaller-than-expected adjusted loss, while raising its full-year sales guidance despite recording multibillion-dollar acquisition-rela…
quartr
MRK: Q2 revenue up 5% to $16.6B; pipeline advances and raised 2026 guidance signal strong outlook
Q2 revenue rose 5% to $16.6B, led by oncology and new launches, with strong progress in pipeline de-risking and regulatory milestones. Guidance for 2026 was raised, with EPS expected at $2.66–$2.76, including a major one-time charge. Confidence in long-term growth remains high.Based on Merck & Comp…
tradingview
Merck reports Q2 2026 sales $16.6B, GAAP loss $0.54/sh; narrows FY26 sales to $66.3–$67.3B
Merck reported second-quarter 2026 revenue of $16.6 billion and a GAAP loss per share of $0.54, driven primarily by a $2.31 per-share charge related to the acquisition of Terns. Non-GAAP loss per share was $0.13 for the quarter; the company narrowed and raised its full‑year sales outlook to $66.3 b…
quartr
MRK: Q2 2026 sales up 5% to $16.6B, with oncology and new launches driving growth
Q2 2026 sales rose 5% to $16.6B, led by oncology and animal health, with new launches fueling growth. Updated 2026 revenue guidance is $66.3B–$67.3B, but EPS guidance was lowered due to a $5.7B acquisition charge. Multiple pipeline and regulatory milestones were achieved.Original document: Merck…
stockstory
What To Expect From Merck’s (MRK) Q2 Earnings
Global pharmaceutical company Merck NYSE:MRKwill be announcing earnings results this Tuesday before market hours. Here’s what investors should know.Merck beat analysts’ revenue expectations last quarter, reporting revenues of $16.29 billion, up 4.9% year on year. It was a strong quarter for the com…
tradingview
Key facts: Merck & Co., Inc. $0.85 Q4 Dividend; China Trial Probe; Ebola Vaccine Aid
Merck (MRK) declared a $0.85 quarterly cash dividend for Q4 2026; record date Sept 15, 2026, payment date Oct 7, 2026.U.S. lawmakers asked Merck (MRK) for details on data protectio
SLS Stock Heads For Worst Month In Over 2 Years — But Retail Bulls ‘Hold’ For AML Readout And Buyout Hopes
Shares of Sellas Life Sciences (SLS) are sliding toward their worst month in over two years, but retail bulls are still buying weakness and holding out for a potential buyout as the company nears a key acute myeloid leukemia (AML) readout.SLS stock SLS stock has fallen 31% so far in July after exte…
CHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the marketing authorization of Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda®…
Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower
The AI and memory-chip rallies may have already minted their biggest winners, but biotech is mounting a breakout of its own, with the XBI biotech ETF sharply outperforming the broader market as cash-rich drugmakers race to buy promising pipelines before blockbuster patent losses begin eroding reven…
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The…
SLS Stock Jumps Ahead Of CEO’s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War
Shares of Sellas Life Sciences (SLS) jumped 3% overnight late Monday as retail traders bet that the final acute myeloid leukemia (AML) readout could turn this week’s Fox appearance into a launchpad for Big Pharma interest.SLS stock surged 12% on Friday to close at $13.19, capping a 3% weekly gain.S…
zacks
MRK Stock Jumps on FDA Nod for Cholesterol-Lowering Pill
Shares of Merck MRK rose more than 3% on Thursday after the company announced that the FDA approved enlicitide as the first oral PCSK9 inhibitor to reduce low-density lipoprotein cholesterol (LDL-C, or bad cholesterol) in adults with hypercholesterolemia (high cholesterol). The drug will be markete…
Why Is PSNL Stock Up 5% After-Hours?
Shares of Personalis (PSNL) rose 5% after-hours on Thursday following rumors that the precision oncology company is exploring strategic options, including a potential sale, after receiving takeover interest from Merck & Co. (MRK) and at least two other parties.Personalis has hired investment banks…
business_wire
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA® (enlicitide) tablets 20 mg as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholes…
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited ASX:IMM; NASDAQ:IMMP (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a significant positive update of the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagi…
SLS Vs MLTX: Retail Traders Race To Pick Merck’s Next Biotech Buyout As Keytruda’s $31.7B Patent Cliff Nears
Sellas Life Sciences (SLS) and MoonLake Immunotherapeutics (MLTX) have emerged as retail’s leading candidates for Merck & Co.’s (MRK) next biotech deal as the drugmaker prepares for life beyond Keytruda.SLS and MLTX each gained more than 2% at the start of overnight trading late Sunday, while MRK e…
dow-jones
Merck Price Target Maintained With a $120.00/Share by Cantor Fitzgerald
Merck Price Target Maintained With a $120.00/Share by Cantor Fitzgerald